Phase I trial of docetaxel and short infusion Gemcitabine given every two weeks for advanced solid tumors

被引：0
|
作者：
Davis, TH
Rigas, JR
Maurer, LH
Pipas, JM
Obrocea, M
Tretter, CP
Smith, EL
Meyer, L
Hammond, S
机构：
[1] Norris Cotton Canc Ctr, Lebanon, NH USA
[2] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
642P
引用
收藏
页码：134 / 134
页数：1
相关论文
共 50 条
  • [21] A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer
    Vasiliki Bozionelou
    Kostas Kalbakis
    Lambros Vamvakas
    Sofia Agelaki
    Nikolaos Androulakis
    Antonia Kalykaki
    Vassilis Georgoulias
    Dimitris Mavroudis
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 785 - 791
  • [22] A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors
    Vokes, EE
    Goh, BC
    Bertucci, D
    Vogelzang, NJ
    Mani, S
    Ratain, MJ
    CANCER, 1999, 86 (03) : 528 - 532
  • [23] Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors
    Brell, Joanna M.
    Krishnamurthi, Smitha S.
    Rath, Linda
    Bokar, Joseph A.
    Savvides, Panayiotis
    Gibbons, Joseph
    Cooney, Matthew M.
    Meropol, Neal J.
    Ivy, Percy
    Dowlati, Afshin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (04) : 547 - 553
  • [24] Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors
    Reid, JM
    Qu, WC
    Safgren, SL
    Ames, MM
    Krailo, MD
    Seibel, NL
    Kuttesch, J
    Holcenberg, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) : 2445 - 2451
  • [25] Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors
    Joanna M. Brell
    Smitha S. Krishnamurthi
    Linda Rath
    Joseph A. Bokar
    Panayiotis Savvides
    Joseph Gibbons
    Matthew M. Cooney
    Neal J. Meropol
    Percy Ivy
    Afshin Dowlati
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 547 - 553
  • [26] A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors
    Werner Hilgers
    Sandrine Faivre
    Stéphanie Chieze
    Jérôme Alexandre
    François Lokiec
    François Goldwasser
    Eric Raymond
    Carmen Kahatt
    Abdelkrim Taamma
    Garry Weems
    John R. MacDonald
    Jean-Louis Misset
    Esteban Cvitkovic
    Investigational New Drugs, 2006, 24 : 311 - 319
  • [27] A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors
    Hilgers, Werner
    Faivre, Sandrine
    Chieze, Stephanie
    Alexandre, Jerome
    Lokiec, Francois
    Goldwasser, Francois
    Raymond, Eric
    Kahatt, Carmen
    Taamma, Abdelkrim
    Weems, Garry
    MacDonald, John R.
    Misset, Jean-Louis
    Cvitkovic, Esteban
    INVESTIGATIONAL NEW DRUGS, 2006, 24 (04) : 311 - 319
  • [28] Phase I trial of pomalidomide given for patients with advanced solid tumors
    Matthew M. Cooney
    Charles Nock
    Joseph Bokar
    Smitha Krishnamurthi
    Joseph Gibbons
    Mary Beth Rodal
    Anne Ness
    Scot C. Remick
    Robert Dreicer
    Afshin Dowlati
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 755 - 761
  • [29] Phase I trial of pomalidomide given for patients with advanced solid tumors
    Cooney, Matthew M.
    Nock, Charles
    Bokar, Joseph
    Krishnamurthi, Smitha
    Gibbons, Joseph
    Rodal, Mary Beth
    Ness, Anne
    Remick, Scot C.
    Dreicer, Robert
    Dowlati, Afshin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (05) : 755 - 761
  • [30] PHASE-I TRIAL OF TAXOL GIVEN AS A 3-HOUR INFUSION EVERY 3 WEEKS
    OCONNELL, JP
    KRIS, MG
    GRALLA, RJ
    WERTHEIM, MS
    YOUNG, CW
    SYKES, M
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1985, 26 (MAR): : 169 - 169
12345